BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 19737942)

  • 1. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.
    Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F
    Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
    Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F
    Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.
    Binh MB; Sastre-Garau X; Guillou L; de Pinieux G; Terrier P; Lagacé R; Aurias A; Hostein I; Coindre JM
    Am J Surg Pathol; 2005 Oct; 29(10):1340-7. PubMed ID: 16160477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.
    Kammerer-Jacquet SF; Thierry S; Cabillic F; Lannes M; Burtin F; Henno S; Dugay F; Bouzillé G; Rioux-Leclercq N; Belaud-Rotureau MA; Stock N
    Hum Pathol; 2017 Jan; 59():34-40. PubMed ID: 27597521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
    Creytens D; Van Gorp J; Speel EJ; Ferdinande L
    Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.
    Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM
    J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical value of fluorescence
    Wang W; Li X; Liu P; Dong Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):228-233. PubMed ID: 37042132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma.
    Segura-Sánchez J; González-Cámpora R; Pareja-Megia MJ; García-Escudero A; Galera-Ruiz H; López-Beltrán A
    Anticancer Res; 2006; 26(6C):4937-42. PubMed ID: 17214366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
    Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
    Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
    Mariño-Enríquez A; Hornick JL; Dal Cin P; Cibas ES; Qian X
    Cancer Cytopathol; 2014 Feb; 122(2):128-37. PubMed ID: 24227706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology.
    Kim YJ; Kim M; Park HK; Yu DB; Jung K; Song K; Choi YL
    Lab Invest; 2019 Sep; 99(9):1309-1320. PubMed ID: 31160689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR.
    Sirvent N; Coindre JM; Maire G; Hostein I; Keslair F; Guillou L; Ranchere-Vince D; Terrier P; Pedeutour F
    Am J Surg Pathol; 2007 Oct; 31(10):1476-89. PubMed ID: 17895748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of MDM2/CDK4 amplification in lipomatous soft tissue tumors from formalin-fixed, paraffin-embedded tissue: comparison of multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH).
    Creytens D; van Gorp J; Ferdinande L; Speel EJ; Libbrecht L
    Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):126-33. PubMed ID: 25679065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of
    Rekhi B; Karnik N; Agrawal R; Shetty O; Patkar S
    Indian J Pathol Microbiol; 2022; 65(1):65-75. PubMed ID: 35074968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma.
    He M; Aisner S; Benevenia J; Patterson F; Harrison LE; Hameed M
    Pathol Res Pract; 2009; 205(6):386-94. PubMed ID: 19186005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High level of CDK4 amplification is a poor prognostic factor in well-differentiated and dedifferentiated liposarcoma.
    Lee SE; Kim YJ; Kwon MJ; Choi DI; Lee J; Cho J; Seo SW; Kim SJ; Shin YK; Choi YL
    Histol Histopathol; 2014 Jan; 29(1):127-38. PubMed ID: 23852861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of MDM2 and CDK4 amplification levels using real-time polymerase chain reaction for the differential diagnosis of liposarcomas and their histologic mimickers.
    Shimada S; Ishizawa T; Ishizawa K; Matsumura T; Hasegawa T; Hirose T
    Hum Pathol; 2006 Sep; 37(9):1123-9. PubMed ID: 16938516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Well-differentiated and dedifferentiated liposarcomas.
    Coindre JM; Pédeutour F; Aurias A
    Virchows Arch; 2010 Feb; 456(2):167-79. PubMed ID: 19688222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.
    Somaiah N; Tap W
    Cancer Treat Rev; 2024 Jan; 122():102668. PubMed ID: 38104352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.
    Saâda-Bouzid E; Burel-Vandenbos F; Ranchère-Vince D; Birtwisle-Peyrottes I; Chetaille B; Bouvier C; Château MC; Peoc'h M; Battistella M; Bazin A; Gal J; Michiels JF; Coindre JM; Pedeutour F; Bianchini L
    Mod Pathol; 2015 Nov; 28(11):1404-14. PubMed ID: 26336885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.